Wall Street analysts forecast that Endo International PLC (NASDAQ:ENDP) (TSE:ENL) will post $0.44 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Endo International’s earnings. The lowest EPS estimate is $0.36 and the highest is $0.66. Endo International reported earnings of $0.67 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 34.3%. The business is scheduled to report its next quarterly earnings report on Tuesday, May 14th.
On average, analysts expect that Endo International will report full-year earnings of $2.17 per share for the current fiscal year, with EPS estimates ranging from $2.05 to $2.25. For the next fiscal year, analysts anticipate that the firm will post earnings of $2.40 per share, with EPS estimates ranging from $1.78 to $3.12. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Endo International.
Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings results on Thursday, February 28th. The company reported $0.75 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.59 by $0.16. The business had revenue of $786.39 million during the quarter, compared to analysts’ expectations of $744.24 million. Endo International had a negative net margin of 35.00% and a negative return on equity of 337.13%. During the same quarter in the prior year, the company posted $0.77 EPS.
Several hedge funds have recently made changes to their positions in the company. LS Investment Advisors LLC purchased a new stake in shares of Endo International in the 4th quarter worth $59,000. Oregon Public Employees Retirement Fund bought a new position in shares of Endo International during the 4th quarter worth $76,000. First Quadrant L P CA bought a new position in shares of Endo International during the 4th quarter worth $92,000. Neuburgh Advisers LLC increased its stake in shares of Endo International by 13.9% during the fourth quarter. Neuburgh Advisers LLC now owns 24,860 shares of the company’s stock valued at $181,000 after buying an additional 3,036 shares during the period. Finally, Neuberger Berman Group LLC purchased a new position in shares of Endo International during the third quarter valued at $202,000. Hedge funds and other institutional investors own 95.69% of the company’s stock.
Shares of NASDAQ:ENDP traded up $0.17 during trading on Monday, hitting $8.37. The stock had a trading volume of 1,756,568 shares, compared to its average volume of 3,171,826. The firm has a market capitalization of $1.84 billion, a P/E ratio of 2.90 and a beta of 1.17. Endo International has a 12 month low of $5.31 and a 12 month high of $18.50.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Recommended Story: How mutual funds make money
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.